Exchange: NASDAQ·Updated 07:48 PM EDT
RYTM logo

RYTMRhythm Pharmaceuticals Inc.

$106.09
$3.60
(3.28%)
Today
Closed $106.09
$2.05
(1.93%)
After Hours
EarningsAug 4
Mkt Cap$7.52B
Vol615,727.00
News
all
press releases
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.read more...
Benzinga
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of Canada
Royal Bank Of Canada increased their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an "outperform" rating in a research report on Wednesday...
MarketBeat
News Placeholder
Wells Fargo & Company Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $144.00
Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the stock an "overweight" rating in a research note on Wednesday...
MarketBeat
News Placeholder
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
Key PointsThe biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug...
Nasdaq News: Markets
News Placeholder
Rhythm Pharmaceuticals Q1 Earnings Call Highlights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported first-quarter 2026 revenue growth as the company began its U.S. commercial launch of IMCIVREE for acquired hypothalamic obesity (HO) and highlighted new regulatory progress in Europe and Japan. First-quarter results show continued IMCIVREE growth Chair...
MarketBeat
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus...
MarketBeat
News Placeholder
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Earnings Beat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Better-Than-Expected Earnings...
MarketBeat
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.